Q2 2025 Mediwound Ltd Earnings Call Transcript
Key Points
- MediWound Ltd (MDWD) reported a 43% sequential revenue growth in the second quarter of 2025, reflecting higher product sales and a more favorable revenue mix.
- The ScarX Value Phase 3 trial is actively enrolling patients, with new collaborations established with Convatech and SCT, engaging global wound care leaders in their clinical programs.
- Nexobrid continues to gain traction in the US market, with a reported 52% year-over-year revenue growth driven by increases in hospital unit orders and the number of ordering centers.
- The commissioning of a new manufacturing facility remains on track for completion by year-end, which is critical to support global growth and meet anticipated demand.
- MediWound Ltd (MDWD) received an additional $3.6 million in non-dilutive funding from the US Department of Defense, bringing the total program funding to $18.2 million, to support the development of a room temperature stable formulation for Nexobrid.
- Operating loss increased to $5.7 million in Q2 2025 compared to $4.5 million in Q2 2024, indicating rising operational costs.
- Net loss for the second quarter was $13.3 million, significantly higher than the $6.3 million loss in the same period last year, driven by $6.6 million in non-cash financial expenses.
- Research and development expenses rose to $3.5 million from $1.9 million in the second quarter of 2024, reflecting increased investment in clinical trials.
- The cash position decreased to $32.9 million as of June 30, 2025, from $43.6 million at year-end 2024, indicating a significant cash burn.
- There is uncertainty regarding the FDA inspection timelines for the new manufacturing facility, which could potentially impact the approval and commercial output schedule.
Good day and welcome to Mediwound second quarter 2025 earnings conference call.
(Operator Instructions) I would now like to turn the conference over to Dan Ferry of LifeSci Advisors. Please go ahead.
Thank you, operator, and welcome everyone. Earlier today, pre-market open, Mediwound issued a press release announcing financial results for the second quarter ended June 30, 2025.
You may access this press release on the company's website under the investors tab. It would ask you to review the full text of our forward-looking statements within this morning's press release.
Before we begin, I would like to remind everyone that statements made during this call, including the Q&A session relating to anyone's expected future performance, future business prospects, or future events or plans, are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1,995.
These statements may involve risks and uncertainties that could cause actual results
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
